Regeneron and AbCellera collaborate on second antibody program

Trending News 🌥️

ABCELLERA ($NASDAQ:ABCL): AbCellera Biologics Inc. is a Canadian biotechnology company that discovers, develops and manufactures antibody therapeutics for the treatment of cancer and other diseases. The company has entered into a collaboration with Regeneron Pharmaceuticals, Inc. to license a second antibody program from AbCellera as part of their ongoing multi-target collaboration. “We are thrilled that Regeneron has chosen to exercise their option to license a second antibody program from us,” said AbCellera CEO Carl Hansen. “This is a testament to the strength of our partnership and the success of our first program together. We look forward to continuing our work with Regeneron to develop innovative new treatments for patients.”

The second program will focus on developing antibodies that target a different protein involved in the immune response. The collaboration between AbCellera and Regeneron is part of a larger trend in the biotechnology industry of companies working together to develop new therapies. This type of collaboration allows companies to pool their resources and expertise to create treatments that would be difficult to develop on their own.

Market Price

On Thursday, AbCellera Biologics Inc. stock opened at $11.8 and closed at $12.1, up by 0.9% from prior closing price of $12.0. The company announced a collaboration with Regeneron Pharmaceuticals, Inc. on a second antibody program. Under the agreement, AbCellera will use its monoclonal antibody discovery platform to identify fully human neutralizing antibodies against an undisclosed target selected by Regeneron.

The companies will jointly develop and commercialize any mAbs that are discovered through the program. This is the second antibody program that the companies have collaborated on; the first program is currently in clinical trials. Live Quote…

About the Company

VI Analysis

Companies with strong fundamentals are usually those with long-term potential. The analysis of ABCELLERA BIOLOGICS below is made simple by the VI app. According to the VI Star Chart, ABCELLERA BIOLOGICS is classified as a ‘gorilla’. Gorilla companies are those that have achieved stable and high revenue or earnings growth due to their strong competitive advantage. Given its strong fundamentals, ABCELLERA BIOLOGICS may be of interest to investors who are looking for companies with long-term potential. Additionally, its high health score of 9/10 with regard to its cashflows and debt indicates that it is a safe company to invest in and that it has the ability to ride out any crisis without the risk of bankruptcy. However, it should be noted that ABCELLERA BIOLOGICS is weak in terms of dividend payouts. More…

VI Peers

Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.

– Ensysce Biosciences Inc ($NASDAQ:ENSC)

Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.

– INmune Bio Inc ($NASDAQ:INMB)

Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.

– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.

Summary

AbCellera Biologics is a Vancouver-based biotech company that is focused on developing next-generation monoclonal antibody therapeutics. The company has a proprietary technology platform that allows for the rapid identification and characterization of monoclonal antibodies from natural sources. AbCellera’s technology has been used to generate antibodies that have been shown to be effective against a variety of diseases, including cancer, infectious diseases, and autoimmune disorders. The company is also collaborating with a number of pharmaceutical and biotech companies on the development of antibody-based therapeutics.